Mogrifiy completes Series A financing round
Cell reprogramming specialist Mogrify Ltd has announced the second closing of its Series A financing of $17m, bringing the total raised to $33m in this round.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1998 entries already.
Entries by Thomas Gabrielczyk
COVID-19 vaccine for poor countries
Moderna Inc. has signed a COVID-19 vaccine supply agreement with vaccination alliance Gavi.
Increase viral RNA extraction throughput with automation
During the global COVID-19 outbreak, BioEcho developed a rapid extraction protocol that reduced the isolation of SARS-CoV-2-RNA to just a few minutes. Currently, BioEcho offers a CE-marked viral RNA/DNA extraction kit and is implementing automated solutions that will allow customers to increase their diagnostics throughput.
ADCendo ApS raises €51m in Series A financing
Danish ADCendo ApS will use the funds from a Series A investment to advance Antibody-Drug Conjugates (ADCs) entering cancer cells through endocytic receptors.
DNA Script bags DARPA funding
DNA Script will receive a $5m DARPA grant as part of the agency’s Nucleic Acids On-Demand World-Wide Program to prevent the next viral pandemic.
First malaria vaccine meets WHO efficacy criteria
Researchers at Novavax and from the University of Oxford reported an efficacy of 77% of their malaria vaccine, R21/Matrix-M from a Phase II trials in Burkina Faso.
European COVID-19 antibody enters Phase III testing
GSK’s and Vir Therapeutics COVID-19 antibody treatment VIR-7831 has entered Phase III testing within the UKs COVID-19 drug testing platform, AGILE
J&J starts European COVID-19 vaccine roll-out
After a positive re-evaluation of J&Js COVID-19 vaccine by the European Medicines Agency (EMA), J&J has re-started to ship 55 million doses to the EU.
Endeavour Medtech Growth II LP closes at $375m
Endeavour Vision has announced the closing of its Heathtech fund Endeavour Medtech Growth II (EMG II) LP at US$375 million in capital commitments.
Record year for Swiss biotech industry
The Swiss biotech industry experienced a record investment in the pandemic year 2020, according to the new Swiss Biotech Report.